Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 57

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 8
Chunk 57
---
 to any material pending legal proceedings, nor are
we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations
or financial condition.

License
Commitments

As
of July 31, 2025, our commitments under certain technology license agreements related to our therapeutic and vaccine development programs
for the next twelve months were approximately $150,000.

Research
& Development Agreements

We
have entered into certain research and development agreements with various collaboration partners and third-party vendors related to
i) the manufacturing of materials necessary for the expected Phase 2 clinical trial of our breast cancer vaccine, ii) the discovery of
new vaccine targets in high incidence malignancies in prostate, lung and colon and iii) the further development of our CAR-T technology.
As of July 31, 2025, future payments the Company may make under these agreements, dependent upon, among other things, development of
analytical methods, formulation feasibility studies, stability testing and results of manufacturing processes, may be approximately $1.8
million and such payments may be made over up to a three-year
period.

11.
SEGMENT INFORMATION

We
follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are
determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating
decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results
of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable
segments, each with different operating and potential revenue generating characteristics: (i) Cancer Vaccines, (ii) CAR-T Therapeutics,
and (iii) Other. The following represents selected financial information for our segments for the three and nine months ended July 31,
2025 and 2024 and as of July 31, 2025 and October 31, 2024 (in thousands):

 SCHEDULE OF SEGMENT INFORMATION

    2025  
    2024  
    2025  
    2024 

    For
    the Three Months Ended July 31,  
    For
    the Nine Months Ended  July 31, 

    2025  
    2024  
    2025  
    2024 
  
    Net
    loss: